FOLD Stock Analysis: Buy, Sell, or Hold?

FOLD - Amicus Therapeutics, Inc

PHARMACEUTICAL PREPARATIONS
$14.49
0.03 (0.21%) ▲
5d: +0.21%
30d: +0.42%
90d: +1.51%
HOLD
MODERATE Confidence
Protect Your FOLD Gains
Analysis Updated: Apr 24, 2026 12:00 AM ET
Earnings: May 13, 2026 0d

Get Alerted When FOLD Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 HOLD: FOLD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$29.50
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$18.32
20.9% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.5x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: FOLD is currently trading at $14.49, which is considered extended relative to its 30-day fair value range of $14.45 to $14.47. The stock's valuation (Forward PE: 17.7) is in line with its historical norms (18.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, FOLD is in a strong uptrend. The price is currently testing key support at $14.45. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $14.45 - $14.47
Company Quality Score 60/100 (HOLD)
Options IV Signal 42th percentile (NORMAL)
Volume Confirmation HIGH
Confidence Score 50.8%

Protect Your Profits

FOLD is technically overbought (RSI 70). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

All Signals

  • BEARISH: Price extended above range
  • NEUTRAL: Options fairly priced (IV 42th percentile)
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($14.50)

Trading Range Analysis

30-Day Trading Range $14.45 - $14.47
Current vs Trading Range EXTENDED
Expected Move (7 Days) ±$2.11 (14.6%)

Support & Resistance Levels

Support Level $14.45
Resistance Level $14.50
Current Trend Strong Uptrend
Technical data as of Apr 24, 2026

Fundamental Context

Forward P/E (Next Year Est.) 17.69
Wall Street Target $14.50 (+0.1%)
Revenue Growth (YoY) 23.7%
Earnings Growth (YoY) -95.5%
Profit Margin -4.3%
Valuation Discount vs History -1.5% cheaper
PE vs Historical 17.7 vs 18.5 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -1.5% (market-implied from PE analysis)
1-Year Target $14.27 (-2%)
2-Year Target $14.06 (-3%)
3-Year Target $13.85 (-4%)
3-Yr Target (if PE normalizes) (PE: 18→19) $14.48 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.6, Growth: 1028.0%) $56.96 (+293%)
Base: (SPY PE: 17.7, Growth: 1028.0%) $48.90 (+238%)
Bear: (PE: 15.0, Growth: 1028.0%) $41.57 (+187%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.7 to 18.5
Stabilization Target: $15.15 (+4.6%)
PE Expansion Potential: +4.6%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: May 21, 2026 6:00 PM ET
Data refreshes hourly during market hours. Next update: 7:00 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Bradley L Campbell SELL 22500 shares 2026-03-02
Bradley L Campbell SELL 75000 shares 2026-01-20
David Michael Clark SELL 25642 shares 2025-12-19

Unlock Insider Activity

See real-time buying/selling by company executives for FOLD.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
AXSM
Axsome Therapeutics Inc
STRONG BUY
19 analysts
$270 58 HOLD
ACLX
Arcellx Inc
STRONG BUY
18 analysts
$113 57 HOLD
BBIO
BridgeBio Pharma Inc
STRONG BUY
19 analysts
$103 62 BUY
CRNX
Crinetics Pharmaceutical…
STRONG BUY
17 analysts
$83 53 HOLD
BNTX
BioNTech SE
STRONG BUY
21 analysts
$126 50 HOLD

Advanced FOLD Option Strategies

Professional options setups generated by AI based on today's FOLD price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for FOLD

FOLD Technical Chart FOLD Price Prediction FOLD Earnings Date FOLD Investment Advisor FOLD Fair Price Analyzer FOLD Options Advisor FOLD Options Chain FOLD Options Analysis FOLD Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals